Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 3, 2015, Pages 636-643

  Rösner Friese, Karen ^a   Kaul, Susanne ^a   Vieths, Stefan ^a   Pfaar, Oliver ^b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

allergen immunotherapy; clinical validation; Environmental exposure chamber; pivotal studies

Indexed keywords

ALLERGEN;

ALLERGEN IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL EXPOSURE CHAMBER; EUROPEAN MEDICINES AGENCY; GRASS POLLEN; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; JAPANESE CEDAR; PLACEBO EFFECT; POLLINATION; PRIORITY JOURNAL; RAGWEED; RAGWEED POLLEN; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; AIR QUALITY CONTROL; CLINICAL TRIAL (TOPIC); DESENSITIZATION; EUROPE; IMMUNOLOGY; PATHOPHYSIOLOGY; POLLEN; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; STANDARDS; UNITED STATES; VALIDATION STUDY;

ALLERGENS; ATMOSPHERE EXPOSURE CHAMBERS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; ENVIRONMENTAL EXPOSURE; EUROPE; HUMANS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES; VALIDATION STUDIES AS TOPIC;

EID: 84924613310     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.10.045     Document Type: Review

References (56)

1. P. Devillier, M. Le Gall, and F. Horak The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy Allergy 66 2011 163 169
2. R.L. Jacobs, D.A. Ramirez, and C.P. Andrews Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen Ann Allergy Asthma Immunol 107 2011 133 138
3. J.H. Day, F. Horak, M.P. Briscoe, G.W. Canonica, S.M. Fineman, and N. Krug The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper Clin Exp Allergy Rev 6 2006 31 59
4. J.H. Day, A.K. Ellis, E. Rafeiro, J.D. Ratz, and M.P. Briscoe Experimental models for the evaluation of treatment of allergic rhinitis Ann Allergy Asthma Immunol 96 2006 263 277
5. R.L. Jacobs, N. Harper, W. He, C.P. Andrews, C.G. Rather, and D.A. Ramirez Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes J Allergy Clin Immunol 130 2012 122 127
6. J.M. Hohlfeld, T. Holland-Letz, M. Larbig, M. Lavae-Mokhtari, E. Wierenga, and M. Kapsenberg Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions Clin Exp Allergy 40 2010 998 1006
7. P.U. Zieglmayer Are results of environmental exposure units transferable to real-life exposure? Curr Opin Allergy Clin Immunol 13 2013 244 248
8. J.A. Bernstein Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: early evidence supporting a paradigm shift in drug investigation? J Allergy Clin Immunol 130 2012 128 129
9. F. Horak, and S. Jager Die Wiener Provokations-Kammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositionstests Wien Klin Wochenschr 99 1987 509 510
10. J.H. Day, and M.P. Briscoe Environmental exposure unit: a system to test anti-allergic treatment Ann Allergy Asthma Immunol 83 1999 83 89
11. J.H. Day, D.L. Buckeridge, R.H. Clark, M.P. Briscoe, and R. Phillips A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis J Allergy Clin Immunol 97 1996 1050 1057
12. J.H. Day, M.P. Briscoe, R.H. Clark, A.K. Ellis, and P. Gervais Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis Ann Allergy Asthma Immunol 79 1997 163 172
13. J.H. Day, M.P. Briscoe, E. Rafeiro, A.K. Ellis, E. Pettersson, and A. Akerlund Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model J Allergy Clin Immunol 105 2000 489 494
14. J.H. Day, M.P. Briscoe, E. Rafeiro, D. Hewlett, D. Chapman, and B. Kramer Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis Allergy Asthma Proc 25 2004 59 68
15. F. Horak, P. Zieglmayer, R. Zieglmayer, and P. Lemell Onset of action of loratadine/montelukast in seasonal allergic rhinitis patients exposed to grass pollen Arzneimittelforschung 60 2010 249 255
16. F. Horak, P. Zieglmayer, R. Zieglmayer, and P. Lemell The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber Inflamm Res 59 2010 391 398
17. F. Horak, P. Stübner, R. Zieglmayer, A. Kawina, M. Moser, and R. Lanz Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis. Efficacy after repeated pollen challenges in the Vienna challenge chamber Clin Drug Investig 23 2003 329 337
18. F. Horak, P. Stübner, R. Zieglmeyer, and A.G. Harris Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure Allergy 58 2003 481 485
19. F. Horak, P. Stübner, R. Zieglmayer, A. Kavina, C. De Vos, and B. Burtin Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis Int Arch Allergy Immunol 125 2001 73 79
20. P. Stübner, F. Horak, R. Zieglmayer, E. Arnaiz, C. Leuratti, and I. Perez Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber Ann Allergy Asthma Immunol 96 2006 37 44
21. P. Stübner, R. Zieglmayer, and F. Horak A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC) Curr Med Res Opin 20 2004 891 902
22. N. Krug, J.M. Hohlfeld, H. Geldmacher, M. Larbig, R. Heermann, and N. Lavallee Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit Allergy 60 2005 354 359
23. R.B. Berkowitz, G.G. Woodworth, C. Lutz, K. Weiler, J. Weiler, and M. Moss Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit Ann Allergy Asthma Immunol 89 2002 38 45
24. F. Horak, P. Stübner, U.E. Berger, B. Marks, J. Toth, and S. Jager Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study J Investig Allergol Clin Immunol 8 1998 165 171
25. J.P. Donovan, D.L. Buckeridge, M.P. Briscoe, R.H. Clark, and J.H. Day Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure Ann Allergy Asthma Immunol 77 1996 74 80
26. W. Meyer, A. Narkus, A.M. Salapatek, and D. Hafner Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber Allergy 68 2013 724 731
27. P. Patel, T. Holdich, K.J. Fischer von Weikersthal-Drachenberg, and B. Huber Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen J Allergy Clin Immunol 133 2014 121 129 e1-2
28. F. Horak, P. Zieglmayer, R. Zieglmayer, P. Lemell, P. Devillier, and A. Montagut Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber J Allergy Clin Immunol 124 2009 471 477
29. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA) Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases 2008 European Medicines Agency London CHMP/EWP/18504/2006
30. US Food and Drug Administration - Center for Drug Evaluation and Research Allergic rhinitis: clinical development programs for drug products Draft Guidance 2000 US Food and Drug Administration Silver Spring (MD)
31. O. Pfaar, P. Demoly, R. Gerth van Wijk, S. Bonini, J. Bousquet, and G.W. Canonica Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper Allergy 69 2014 854 867
32. N. Krug, J.M. Hohlfeld, M. Larbig, A. Buckendahl, P. Badorrek, and H. Geldmacher Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis Clin Exp Allergy 33 2003 1667 1674
33. K. Ito, T. Terada, A. Yuki, T. Ichihara, S. Hyo, and R. Kawata Preliminary study of a challenge test to the patients with Japanese cedar pollinosis using an environmental exposure unit Auris Nasus Larynx 37 2010 694 699
34. K. Hashiguchi, H. Tang, T. Fujita, K. Suematsu, S. Tsubaki, and H. Nagakura Validation study of the OHIO Chamber in patients with Japanese cedar pollinosis Int Arch Allergy Immunol 149 2009 141 149
35. J.H. Day, M. Briscoe, and M.D. Widlitz Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit J Allergy Clin Immunol 101 1998 638 645
36. T. Enomoto, T. Ide, and S. Ogino Construction of an environmental exposure unit and investigation of the effects of cetirizine hydrochloride on symptoms of cedar pollinosis in Japan J Investig Allergol Clin Immunol 17 2007 173 181
37. S.M. Rønborg, H. Mosbech, C.R. Johnsen, and L.K. Poulsen Exposure chamber for allergen challenge. The development and validation of a new concept Allergy 51 1996 82 88
38. A. Yuki, T. Terada, T. Ichihara, K. Fujii, S. Hyo, and R. Kawata Evaluating the effects of testing period on pollinosis symptoms using an allergen challenge chamber Allergol Int 60 2011 533 539
39. P. Badorrek, M. Dick, H. Hecker, F. Schaumann, A.R. Sousa, and R. Murdoch Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season Ann Allergy Asthma Immunol 106 2011 336 341
40. S.M. Rønborg, H. Mosbech, and L.K. Poulsen Exposure chamber for allergen challenge. A placebo-controlled, double-blind trial in house-dust-mite asthma Allergy 52 1997 821 828
41. J.H. Day, M. Briscoe, E. Rafeiro, D. Chapman, and B. Kramer Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system Ann Allergy Asthma Immunol 87 2001 474 481
42. F. Horak, S. Jager, U. Berger, J. Toth, G. Nirnberger, and H.J. Kyrein Controlled exposure to mite allergen for a dose-finding of dimethindene maleate (DMM) Agents Actions 1994 41 Spec No:C124
43. F. Horak, P. Stübner, R. Zieglmayer, and A.G. Harris Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit J Allergy Clin Immunol 109 2002 956 961
44. A.K. Ellis, J.D. Ratz, A.G. Day, and J.H. Day Factors that affect the allergic rhinitis response to ragweed allergen exposure Ann Allergy Asthma Immunol 104 2010 293 298
45. M.J. Radcliffe, G.T. Lewith, P. Prescott, M.K. Church, and S.T. Holgate Do skin prick and conjunctival provocation tests predict symptom severity in seasonal allergic rhinoconjunctivitis? Clin Exp Allergy 36 2006 1488 1493
46. J. Toth, C. Schultze-Werninghaus, B. Marks, A.F. Temmel, P. Stubner, and S. Jager Environmental priming influences allergen-specific nasal reactivity Allergy 53 1998 1172 1177
47. J.T. Connell Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis J Allergy 43 1969 33 44
48. P. Patel, C. D'Andrea, and H.J. Sacks Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber Am J Rhinol 21 2007 499 503
49. F. Horak, S. Jäger, J. Toth, and U. Berger Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber Arzneimittelforschung 46 1996 1077 1081
50. W.T. Barchuk, A.M. Salapatek, T. Ge, P. D'Angelo, and X. Liu A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion J Allergy Clin Immunol 132 2013 838 846 e1-6
51. O. Pfaar, J. Kleine-Tebbe, K. Hörmann, and L. Klimek Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 31 2011 289 309
52. L. Van Overtvelt, V. Baron-Bodo, S. Horiot, H. Moussu, C. Ricarte, and F. Horak Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy Allergy 66 2011 1530 1537
53. M. Bonvalet, H. Moussu, E. Wambre, C. Ricarte, S. Horiot, and A.C. Rimaniol Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy Clin Exp Allergy 42 2012 1745 1755
54. V. Baron-Bodo, S. Horiot, A. Lautrette, H. Chabre, A.S. Drucbert, and P.M. Danzé Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy Clin Exp Allergy 43 2013 1362 1373
55. A. Zimmer, J. Bouley, M. Le Mignon, E. Pliquet, S. Horiot, and M. Turfkruyer A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy J Allergy Clin Immunol 129 2012 1020 1030
56. M. Makatsori, O. Pfaar, R. Lleonart, and M.A. Calderon Recombinant allergen immunotherapy: clinical evidence of efficacy - a review Curr Allergy Asthma Rep 13 2013 371 380